SUPPLEMENT

Q3 2024 — Financial disclosures

Q3 2024PDF · 10 pages1.1 MB
Merck & Co., Inc.
Financial Highlights Package
Third Quarter 2024
Table of Contents
Table 1: GAAP P&L....................................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2
Table 2a: GAAP to Non-GAAP Reconciliation 3Q24 and Sept YTD 24.......3
Table 2b: GAAP to Non-GAAP Reconciliation 3Q23 and Sept YTD 23.......4
Table 3: Sales - Current Year and Prior Year by Quarter..........................5
Table 3a: Sales – U.S. / International 3Q24................................................6
Table 3b: Sales – U.S. / International Sept YTD 24.. .................................7
Table 3c: Sales – Pharmaceutical Geographic Split...................................8
Table 4: Other (Income) Expense ............................................................9

-- 1 of 10 --

Sales 	16,657	$ 	15,962	$ 	4% 	48,544	$ 	45,485	$ 	7%
Costs, Expenses and Other
Cost of sales 	4,080 	4,264 	-4% 	11,365 	12,214 	-7%
Selling, general and administrative 	2,731 	2,519 	8% 	7,952 	7,700 	3%
Research and development 	5,862 	3,307 	77% 	13,354 	20,904 	-36%
Restructuring costs 	56 	126 	-56% 	258 	344 	-25%
Other (income) expense, net 	(162) 	126 	* 	(151) 	388 	*
Income Before Taxes 	4,090 	5,620 	-27% 	15,766 	3,935 	*
Taxes on Income 	929 	870 	2,377 	2,332
Net Income 	3,161 	4,750 	-33% 	13,389 	1,603 	*
Less: Net Income Attributable to Noncontrolling Interests 	4 	5 	15 	12
Net Income Attributable to Merck & Co., Inc. 	3,157	$ 	4,745	$ 	-33% 	13,374	$ 	1,591	$ 	*
Earnings per Common Share Assuming Dilution 	1.24	$ 	1.86	$ 	-33% 	5.26	$ 	0.62	$ 	*
Average Shares Outstanding Assuming Dilution 	2,541 	2,546 	2,543 	2,549
Tax Rate 	22.7% 	15.5% 	15.1% 	59.3%
* 100% or greater
GAAP
% Change
3Q24 	3Q23
GAAP
% Change	Sep YTD
2024
Sep YTD
2023
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
1

-- 2 of 10 --

Sales 	15,775	$ 	16,112	$ 	16,657	$ 	48,544	$ 	14,487	$ 	15,035	$ 	15,962	$ 	45,485	$ 	14,630	$ 	60,115	$ 	4% 	7%
Costs, Expenses and Other
Cost of sales 	3,540 	3,745 	4,080 	11,365 	3,926 	4,024 	4,264 	12,214 	3,911 	16,126 	-4% 	-7%
Selling, general and administrative 	2,483 	2,739 	2,731 	7,952 	2,479 	2,702 	2,519 	7,700 	2,804 	10,504 	8% 	3%
Research and development 	3,992 	3,500 	5,862 	13,354 	4,276 	13,321 	3,307 	20,904 	9,628 	30,531 	77% 	-36%
Restructuring costs 	123 	80 	56 	258 	67 	151 	126 	344 	255 	599 	-56% 	-25%
Other (income) expense, net 	(33) 	42 	(162) 	(151) 	89 	172 	126 	388 	78 	466 	* 	*
Income (Loss) Before Taxes 	5,670 	6,006 	4,090 	15,766 	3,650 	(5,335) 	5,620 	3,935 	(2,046) 	1,889 	-27% 	*
Income Tax Provision (Benefit) 	903 	545 	929 	2,377 	825 	637 	870 	2,332 	(821) 	1,512
Net Income (Loss) 	4,767 	5,461 	3,161 	13,389 	2,825 	(5,972) 	4,750 	1,603 	(1,225) 	377 	-33% 	*
Less: Net Income Attributable to Noncontrolling Interests 	5 	6 	4 	15 	4 	3 	5 	12 	1 	12
Net Income (Loss) Attributable to Merck & Co., Inc. 	4,762	$ 	5,455	$ 	3,157	$ 	13,374	$ 	2,821	$ 	(5,975)	$ 	4,745	$ 	1,591	$ 	(1,226)	$ 	365	$ 	-33% 	*
Earnings (Loss) per Common Share Assuming Dilution (1) 	1.87	$ 	2.14	$ 	1.24	$ 	5.26	$ 	1.11	$ 	(2.35)	$ 	1.86	$ 	0.62	$ 	(0.48)	$ 	0.14	$ 	-33% 	*
Average Shares Outstanding Assuming Dilution (1) 	2,544 	2,544 	2,541 	2,543 	2,551 	2,539 	2,546 	2,549 	2,533 	2,547
Tax Rate 	15.9% 	9.1% 	22.7% 	15.1% 	22.6% 	-11.9% 	15.5% 	59.3% 	40.1% 	80.0%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Because the company recorded a net loss in the second quarter and the fourth quarter of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the
effect would have been anti-dilutive.
2024
2Q 	3Q 	Sep YTD	1Q 	1Q 	2Q 	3Q 	4Q 	Full Year
2023
Sep YTD 	Sep YTD
% Change
Table 1a
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
3Q
2

-- 3 of 10 --

Third Quarter
Cost of sales 	4,080	$ 	639 	192 	831 	3,249	$
Selling, general and administrative 	2,731 	43 	31 	74 	2,657
Research and development 	5,862 	24 	24 	5,838
Restructuring costs 	56 	56 	56 	–
Other (income) expense, net 	(162) 	(27) 	58 	31 	(193)
Income Before Taxes 	4,090 	(679) 	(279) 	(58) 	(1,016) 	5,106
Income Tax Provision (Benefit) 	929 	(129) (3) 	(46) (3) 	(13) (3) 	(188) 	1,117
Net Income 	3,161 	(550) 	(233) 	(45) 	(828) 	3,989
Net Income Attributable to Merck & Co., Inc. 	3,157 	(550) 	(233) 	(45) 	(828) 	3,985
Earnings per Common Share Assuming Dilution 	1.24	$ 	(0.22) 	(0.09) 	(0.02) 	(0.33) 	1.57	$
Tax Rate 	22.7% 	21.9%
Sep YTD
Cost of sales 	11,365	$ 	1,708 	374 	2,082 	9,283	$
Selling, general and administrative 	7,952 	88 	67 	155 	7,797
Research and development 	13,354 	60 	2 	62 	13,292
Restructuring costs 	258 	258 	258 	–
Other (income) expense, net 	(151) 	(48) 	(107) 	(155) 	4
Income Before Taxes 	15,766 	(1,808) 	(701) 	107 	(2,402) 	18,168
Income Tax Provision (Benefit) 	2,377 	(350) (3) 	(118) (3) 	23 (3) 	(259) (4) 	(704) 	3,081
Net Income 	13,389 	(1,458) 	(583) 	84 	259 	(1,698) 	15,087
Net Income Attributable to Merck & Co., Inc. 	13,374 	(1,458) 	(583) 	84 	259 	(1,698) 	15,072
Earnings per Common Share Assuming Dilution 	5.26	$ 	(0.57) 	(0.23) 	0.03 	0.10 	(0.67) 	5.93	$
Tax Rate 	15.1% 	17.0%
Only the line items that are affected by non-GAAP adjustments are shown.
MERCK & CO., INC.
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
GAAP 	Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Table 2a
Certain Other Items 	Adjustment Subtotal 	Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing
non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting
purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The
non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to
acquisitions and divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets and Animal Health intangible asset impairment charges. Amounts included in other (income)
expense, net, primarily reflect royalty income related to the prior termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairments associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(4) Represents a benefit due to a reduction in reserves for unrecognized income tax benefits resulting from the expiration of the statute of limitations for assessments related to the 2019 federal tax return year.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
3

-- 4 of 10 --

Third Quarter
Cost of sales 	4,264	$ 	552 	33 	585 	3,679	$
Selling, general and administrative 	2,519 	17 	40 	57 	2,462
Research and development 	3,307 	10 	10 	3,297
Restructuring costs 	126 	126 	126 	–
Other (income) expense, net 	126 	(24) 	17 	(7) 	133
Income Before Taxes 	5,620 	(555) 	(199) 	(17) 	(771) 	6,391
Income Tax Provision (Benefit) 	870 	(53) (4) 	(32) (4) 	(4) (4) 	(89) 	959
Net Income 	4,750 	(502) 	(167) 	(13) 	(682) 	5,432
Net Income Attributable to Merck & Co., Inc. 	4,745 	(502) 	(167) 	(13) 	(682) 	5,427
Earnings per Common Share Assuming Dilution 	1.86	$ 	(0.20) 	(0.07) 	– 	(0.27) 	2.13	$
Tax Rate 	15.5% 	15.0%
Sep YTD
Cost of sales 	12,214	$ 	1,564 	94 	1,658 	10,556	$
Selling, general and administrative 	7,700 	62 	93 	155 	7,545
Research and development 	20,904 	29 	1 	30 	20,874
Restructuring costs 	344 	344 	344 	–
Other (income) expense, net 	388 	(12) 	(218) 	573 (3) 	343 	45
Income Before Taxes 	3,935 	(1,643) 	(532) 	218 	(573) 	(2,530) 	6,465
Income Tax Provision (Benefit) 	2,332 	(249) (4) 	(88) (4) 	47 (4) 	(60) (4) 	(350) 	2,682
Net Income 	1,603 	(1,394) 	(444) 	171 	(513) 	(2,180) 	3,783
Net Income Attributable to Merck & Co., Inc. 	1,591 	(1,394) 	(444) 	171 	(513) 	(2,180) 	3,771
Earnings per Common Share Assuming Dilution 	0.62	$ 	(0.55) 	(0.18) 	0.07 	(0.20) 	(0.86) 	1.48	$
Tax Rate 	59.3% 	41.5%
Only the line items that are affected by non-GAAP adjustments are shown.
Adjustment Subtotal 	Non-GAAP
MERCK & CO., INC.
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b
GAAP 	Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Certain Other Items
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that
providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and
forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP
information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to
acquisitions and divestitures. Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, primarily reflect royalty income,
partially offset by an increase in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture. Additionally, the nine-month period includes a $37
million loss on the sale of a business.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(3) Reflects a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation.
(4) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
4

-- 5 of 10 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
2024 	2023 	3Q 	Sep YTD
1Q 	2Q 	3Q 	Sep YTD 	1Q 	2Q 	3Q 	Sep YTD 	Nom % 	Ex-Exch % 	Nom % 	Ex-Exch %
TOTAL SALES (1) 	$15,775 	$16,112 	$16,657 	$48,544 	$14,487 	$15,035 	$15,962 	$45,485 	4 	7 	7 	10
PHARMACEUTICAL 	14,006 	14,408 	14,943 	43,358 	12,721 	13,457 	14,263 	40,442 	5 	8 	7 	10
Oncology
Keytruda 	6,947 	7,270 	7,429 	21,646 	5,795 	6,271 	6,338 	18,403 	17 	21 	18 	22
Alliance Revenue – Lynparza (2) 	292 	317 	337 	947 	275 	310 	299 	884 	13 	13 	7 	8
Alliance Revenue – Lenvima (2) 	255 	249 	251 	755 	232 	242 	260 	734 	-3 	-4 	3 	3
Welireg 	85 	126 	139 	349 	42 	50 	54 	146 	156 	157 	138 	139
Alliance Revenue – Reblozyl (3) 	71 	90 	100 	261 	43 	47 	52 	142 	91 	91 	84 	84
Vaccines (4)
Gardasil/Gardasil 9 	2,249 	2,478 	2,306 	7,032 	1,972 	2,458 	2,585 	7,015 	-11 	-10 	- 	3
ProQuad/M-M-R II/Varivax 	570 	617 	703 	1,891 	528 	582 	713 	1,823 	-1 	-1 	4 	4
Vaxneuvance 	219 	189 	239 	647 	106 	168 	214 	488 	12 	13 	33 	34
RotaTeq 	216 	163 	193 	572 	297 	131 	156 	584 	24 	25 	-2 	-1
Pneumovax 23 	61 	59 	68 	188 	96 	92 	140 	327 	-51 	-51 	-42 	-40
Hospital Acute Care
Bridion 	440 	455 	420 	1,315 	487 	502 	424 	1,413 	-1 	- 	-7 	-6
Prevymis 	174 	188 	208 	570 	129 	143 	157 	430 	32 	36 	33 	36
Dificid 	73 	92 	96 	261 	65 	76 	74 	215 	31 	31 	21 	21
Zerbaxa 	56 	62 	64 	182 	50 	54 	53 	157 	22 	25 	16 	19
Noxafil 	56 	45 	41 	141 	60 	55 	51 	167 	-20 	-13 	-15 	-5
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 	98 	106 	102 	306 	99 	68 	92 	259 	11 	11 	18 	18
Winrevair 	70 	149 	219 	- 	- 	- 	-
Adempas (6) 	70 	72 	72 	214 	59 	65 	65 	189 	11 	13 	13 	15
Virology
Lagevrio 	350 	110 	383 	843 	392 	203 	640 	1,236 	-40 	-36 	-32 	-27
Isentress/Isentress HD 	111 	89 	102 	302 	123 	136 	119 	377 	-14 	-10 	-20 	-16
Delstrigo 	56 	60 	65 	180 	44 	50 	54 	148 	21 	25 	22 	26
Pifeltro 	42 	39 	42 	123 	34 	38 	37 	109 	14 	15 	13 	14
Neuroscience
Belsomra 	46 	53 	78 	177 	56 	63 	58 	176 	35 	40 	- 	7
Immunology
Simponi 	184 	172 	189 	545 	180 	180 	179 	539 	5 	7 	1 	2
Remicade 	39 	35 	41 	115 	51 	48 	45 	144 	-9 	-5 	-20 	-16
Diabetes (7)
Januvia 	419 	405 	278 	1,102 	551 	511 	581 	1,642 	-52 	-49 	-33 	-30
Janumet 	251 	224 	204 	679 	329 	354 	255 	937 	-20 	-13 	-28 	-23
Other Pharmaceutical (8) 	576 	573 	644 	1,796 	626 	560 	568 	1,758 	13 	15 	2 	5
ANIMAL HEALTH 	1,511 	1,482 	1,487 	4,480 	1,491 	1,456 	1,400 	4,347 	6 	11 	3 	7
Livestock 	850 	837 	886 	2,573 	849 	807 	874 	2,530 	1 	7 	2 	7
Companion Animal 	661 	645 	601 	1,907 	642 	649 	526 	1,817 	14 	17 	5 	7
Other Revenues (9) 	258 	222 	227 	706 	275 	122 	299 	696 	-24 	-22 	2 	4
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(7) Total Diabetes sales were $745 million, $715 million and $592 million in the first, second and third quarter of 2024, respectively, and $950 million, $951 million and $924
million in the first, second and third quarter of 2023, respectively.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging
activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $61 million, $15 million and $15 million in the first, second
and third quarter of 2024, respectively, and $51 million, $3 million and $65 million in the first, second and third quarter of 2023, respectively.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $3,424 million, $3,656 million and $3,675 million in the first, second and third quarter of 2024, respectively, and $3,133 million, $3,557 million
and $4,002 million in the first, second and third quarter of 2023, respectively.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(6) Net product sales in Merck's marketing territories.
5

-- 6 of 10 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
THIRD QUARTER 2024
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
Global 	U.S. 	International
3Q 2024 	3Q 2023 % Change 	3Q 2024 	3Q 2023 % Change 	3Q 2024 	3Q 2023 % Change
TOTAL SALES (1) 	$16,657 	$15,962 	4 	$8,736 	$7,715 	13 	$7,922 	$8,247 	-4
PHARMACEUTICAL 	14,943 	14,263 	5 	8,227 	7,153 	15 	6,717 	7,110 	-6
Oncology
Keytruda 	7,429 	6,338 	17 	4,500 	3,795 	19 	2,929 	2,543 	15
Alliance Revenue – Lynparza (2) 	337 	299 	13 	161 	153 	5 	177 	146 	21
Alliance Revenue – Lenvima (2) 	251 	260 	-3 	173 	160 	9 	78 	100 	-22
Welireg 	139 	54 	156 	127 	51 	148 	12 	3 	*
Alliance Revenue – Reblozyl (3) 	100 	52 	91 	82 	43 	93 	18 	10 	83
Vaccines (4)
Gardasil/Gardasil 9 	2,306 	2,585 	-11 	1,020 	838 	22 	1,285 	1,746 	-26
ProQuad/M-M-R II/Varivax 	703 	713 	-1 	572 	567 	1 	131 	146 	-10
Vaxneuvance 	239 	214 	12 	137 	182 	-25 	103 	33 	*
RotaTeq 	193 	156 	24 	131 	108 	21 	62 	48 	28
Pneumovax 23 	68 	140 	-51 	19 	42 	-54 	49 	98 	-50
Hospital Acute Care
Bridion 	420 	424 	-1 	339 	265 	28 	81 	159 	-49
Prevymis 	208 	157 	32 	101 	70 	43 	107 	87 	24
Dificid 	96 	74 	31 	83 	69 	20 	13 	5 	190
Zerbaxa 	64 	53 	22 	39 	29 	34 	26 	24 	6
Noxafil 	41 	51 	-20 	1 	4 	-85 	40 	47 	-15
Cardiovascular
Winrevair 	149 	- 	147 	- 	3 	-
Alliance Revenue - Adempas/Verquvo (5) 	102 	92 	11 	96 	96 	-1 	7 	-4 	*
Adempas (6) 	72 	65 	11 	72 	65 	11
Virology
Lagevrio 	383 	640 	-40 	84 	- 	299 	640 	-53
Isentress/Isentress HD 	102 	119 	-14 	54 	58 	-6 	48 	61 	-21
Delstrigo 	65 	54 	21 	15 	13 	15 	50 	40 	23
Pifeltro 	42 	37 	14 	31 	27 	12 	12 	10 	20
Neuroscience
Belsomra 	78 	58 	35 	20 	23 	-12 	58 	35 	66
Immunology
Simponi 	189 	179 	5 	189 	179 	5
Remicade 	41 	45 	-9 	41 	45 	-9
Diabetes (7)
Januvia 	278 	581 	-52 	67 	328 	-80 	211 	252 	-16
Janumet 	204 	255 	-20 	15 	43 	-67 	190 	211 	-10
Other Pharmaceutical (8) 	644 	568 	13 	213 	189 	13 	426 	381 	12
ANIMAL HEALTH 	1,487 	1,400 	6 	487 	462 	6 	999 	938 	6
Livestock 	886 	874 	1 	194 	205 	-5 	692 	669 	3
Companion Animal 	601 	526 	14 	293 	257 	14 	307 	269 	14
Other Revenues (9) 	227 	299 	-24 	22 	100 	-78 	206 	199 	4
*200% or greater
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $592 million and $924 million on a global basis in the third quarter of 2024 and 2023, respectively.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $15
million and $65 million on a global basis in the third quarter of 2024 and 2023, respectively.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $3,675 million and $4,002 million on a global basis in the third quarter of 2024 and 2023, respectively.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and
commercialization costs.
6

-- 7 of 10 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
SEPTEMBER YEAR-TO-DATE 2024
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
Global 	U.S. 	International
Sep YTD
2024
Sep YTD
2023 	% Change 	Sep YTD 2024
Sep YTD
2023 	% Change
Sep YTD
2024
Sep YTD
2023 	% Change
TOTAL SALES (1) 	$48,544 	$45,485 	7 	$24,089 	$21,393 	13 	$24,455 	$24,092 	2
PHARMACEUTICAL 	43,358 	40,442 	7 	22,563 	19,840 	14 	20,795 	20,602 	1
Oncology
Keytruda 	21,646 	18,403 	18 	13,031 	11,142 	17 	8,614 	7,261 	19
Alliance Revenue – Lynparza (2) 	947 	884 	7 	449 	439 	2 	498 	445 	12
Alliance Revenue – Lenvima (2) 	755 	734 	3 	523 	476 	10 	233 	258 	-10
Welireg 	349 	146 	138 	320 	141 	128 	29 	6 	*
Alliance Revenue – Reblozyl (3) 	261 	142 	84 	215 	108 	99 	45 	33 	36
Vaccines (4)
Gardasil/Gardasil 9 	7,032 	7,015 	- 	2,045 	1,718 	19 	4,988 	5,297 	-6
ProQuad/M-M-R II/Varivax 	1,891 	1,823 	4 	1,500 	1,435 	5 	391 	388 	1
Vaxneuvance 	647 	488 	33 	397 	423 	-6 	251 	65 	*
RotaTeq 	572 	584 	-2 	388 	381 	2 	185 	203 	-9
Pneumovax 23 	188 	327 	-42 	36 	105 	-66 	152 	223 	-32
Hospital Acute Care
Bridion 	1,315 	1,413 	-7 	1,020 	841 	21 	296 	572 	-48
Prevymis 	570 	430 	33 	265 	186 	43 	305 	244 	25
Dificid 	261 	215 	21 	231 	199 	16 	30 	16 	93
Zerbaxa 	182 	157 	16 	106 	86 	23 	77 	71 	8
Noxafil 	141 	167 	-15 	9 	29 	-69 	132 	138 	-4
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 	306 	259 	18 	283 	249 	14 	22 	10 	123
Winrevair 	219 	- 	216 	- 	3 	-
Adempas (6) 	214 	189 	13 	214 	189 	13
Virology
Lagevrio 	843 	1,236 	-32 	144 	- 	699 	1,236 	-43
Isentress/Isentress HD 	302 	377 	-20 	147 	165 	-11 	155 	212 	-27
Delstrigo 	180 	148 	22 	42 	37 	13 	139 	110 	26
Pifeltro 	123 	109 	13 	86 	78 	10 	37 	31 	20
Neuroscience
Belsomra 	177 	176 	- 	53 	60 	-11 	124 	117 	6
Immunology
Simponi 	545 	539 	1 	545 	539 	1
Remicade 	115 	144 	-20 	115 	144 	-20
Diabetes (7)
Januvia 	1,102 	1,642 	-33 	428 	842 	-49 	674 	800 	-16
Janumet 	679 	937 	-28 	70 	182 	-62 	610 	755 	-19
Other Pharmaceutical (8) 	1,796 	1,758 	2 	559 	518 	8 	1,232 	1,239 	-1
ANIMAL HEALTH 	4,480 	4,347 	3 	1,417 	1,418 	- 	3,063 	2,929 	5
Livestock 	2,573 	2,530 	2 	529 	543 	-3 	2,044 	1,987 	3
Companion Animal 	1,907 	1,817 	5 	888 	875 	1 	1,019 	942 	8
Other Revenues (9) 	706 	696 	2 	109 	135 	-19 	597 	561 	6
*200% or greater
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $2,053 million and $2,826 million on a global basis for September YTD 2024 and 2023, respectively.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $91
million and $118 million on a global basis for September YTD 2024 and 2023, respectively.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $10,755 million and $10,692 million on a global basis for September YTD 2024 and 2023, respectively.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and
commercialization costs.
7

-- 8 of 10 --

MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3c
2024 	2023 	% Change
1Q 	2Q 	3Q 	Sep YTD 	1Q 	2Q 	3Q 	Sep YTD 	4Q 	Full Year 	3Q 	Sep YTD
TOTAL PHARMACEUTICAL 	$14,006 	$14,408 	$14,943 	$43,358 	$12,721 	$13,457 	$14,263 	$40,442 	$13,141 	$53,583 	5 	7
United States 	6,936 	7,399 	8,227 	22,563 	6,117 	6,570 	7,153 	19,840 	6,698 	26,539 	15 	14
% Pharmaceutical Sales 	49.5% 	51.4% 	55.1% 	52.0% 	48.1% 	48.8% 	50.1% 	49.1% 	51.0% 	49.5%
Europe (1) 	2,555 	2,572 	2,620 	7,748 	2,326 	2,401 	2,497 	7,224 	2,491 	9,715 	5 	7
% Pharmaceutical Sales 	18.2% 	17.9% 	17.5% 	17.9% 	18.3% 	17.8% 	17.5% 	17.9% 	19.0% 	18.1%
China 	1,744 	1,790 	996 	4,530 	1,694 	1,887 	1,674 	5,255 	1,456 	6,710 	-40 	-14
% Pharmaceutical Sales 	12.5% 	12.4% 	6.7% 	10.4% 	13.3% 	14.0% 	11.7% 	13.0% 	11.1% 	12.5%
Japan 	802 	664 	919 	2,386 	737 	652 	1,062 	2,451 	629 	3,081 	-13 	-3
% Pharmaceutical Sales 	5.7% 	4.6% 	6.2% 	5.5% 	5.8% 	4.8% 	7.4% 	6.1% 	4.8% 	5.7%
Latin America 	601 	661 	730 	1,992 	470 	566 	696 	1,731 	596 	2,328 	5 	15
% Pharmaceutical Sales 	4.3% 	4.6% 	4.9% 	4.6% 	3.7% 	4.2% 	4.9% 	4.3% 	4.5% 	4.3%
Asia Pacific (other than China and Japan) 	580 	595 	669 	1,844 	703 	705 	636 	2,045 	616 	2,661 	5 	-10
% Pharmaceutical Sales 	4.1% 	4.1% 	4.5% 	4.3% 	5.5% 	5.2% 	4.5% 	5.1% 	4.7% 	5.0%
Eastern Europe/Middle East/Africa 	395 	353 	400 	1,147 	381 	370 	301 	1,052 	299 	1,351 	33 	9
% Pharmaceutical Sales 	2.8% 	2.4% 	2.7% 	2.6% 	3.0% 	2.7% 	2.1% 	2.6% 	2.3% 	2.5%
Canada 	138 	143 	133 	414 	141 	127 	133 	401 	138 	540 	- 	3
% Pharmaceutical Sales 	1.0% 	1.0% 	0.9% 	1.0% 	1.1% 	0.9% 	0.9% 	1.0% 	1.1% 	1.0%
Other 	255 	231 	249 	734 	152 	179 	111 	443 	218 	658 	124 	66
% Pharmaceutical Sales 	1.9% 	1.6% 	1.5% 	1.7% 	1.2% 	1.6% 	0.9% 	0.9% 	1.5% 	1.4%
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
8

-- 9 of 10 --

OTHER (INCOME) EXPENSE, NET
3Q24 	3Q23
Sep YTD
2024
Sep YTD
2023
Interest income 	(127)	$ 	(73)	$ 	(269)	$ 	(295)	$
Interest expense 	330 	317 	943 	836
Exchange losses 	33 	85 	177 	208
Loss (income) from investments in equity securities, net (1) 	31 	33 	(169) 	(240)
Net periodic defined benefit plan (credit) cost other than service cost 	(157) 	(138) 	(476) 	(364)
Other, net 	(272) 	(98) 	(357) 	243
Total 	(162)	$ 	126	$ 	(151)	$ 	388	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment
funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from
ownership interests in investment funds are accounted for on a one quarter lag.
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
9

-- 10 of 10 --